Skip to content
2000
Volume 15, Issue 17
  • ISSN: 1568-0266
  • E-ISSN: 1873-4294

Abstract

Cholinesterase inhibition is the only current validated target in clinics in the treatment of Alzheimer’s disease (AD). Therefore, there is continuous interest in the development and discovery of novel cholinesterase inhibitory molecules. Coumarins, beside their employment in other pharmacological groups, have also attracted attention to be utilized in cholinesterase inhibitory molecule discovery and development. Numerous studies so far indicated the natural and synthetic coumarin analogues that have the potential to inhibit acetylcholinesterase and butyrylcholinesterase enzymes. Since the pathophysiology of AD is highly complex and, in particular, monoamine oxidase (MAO) inhibitors are also utilized in clinic for disease symptoms, coumarin analogues, either natural or synthetic, that have the potential to inhibit cholinesterase or MAO enzymes are summarized within this review.

Loading

Article metrics loading...

/content/journals/ctmc/10.2174/1568026615666150427113103
2015-09-01
2025-05-28
Loading full text...

Full text loading...

/content/journals/ctmc/10.2174/1568026615666150427113103
Loading

  • Article Type:
    Research Article
Keyword(s): Alzheimer’s disease; Cholinesterase inhibition; Coumarin; Monoamine oxidase
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test